aO-conotoxin GeXIVA disulfide bond isomers Human and rat nAChRs a9a10 nAChR subtype and its mutants Differential sensitivity Mechanism of action a b s t r a c t Nicotinic acetylcholine receptor (nAChR) subtypes exhibit distinct neuropharmacological properties that are involved in a range of neuropathological conditions, including pain, addiction, epilepsy, autism, schizophrenia, Tourette's syndrome, Alzheimer's and Parkinson's diseases, as well as many types of cancer.
Introduction
For centuries, the shells of Conus snails have been coveted and collected owing to their beauty, but with this beauty comes danger; cone snails are venomous, immobilizing their prey using a complex concoction of toxins. Each concoction contains a unique complement of a thousand or more diverse components (Davis et al., 2009; Lavergne et al., 2015) . Given the existence of more than 800 species of cone snails (Puillandre et al., 2015; Uribe et al., 2017) (REF) , the library of toxins is immense. A number of cases of human fatalities from cone snail envenomation have occurred, and reports of "painless death" sparked interest in the analgesic properties of the venom (Livett et al., 2006) . Many of the venom compounds, which are small disulfide-rich peptides called conotoxins, have been developed into subtype-selective probes for receptors and ion channels. The sequences of conotoxins are compiled in an online database, ConoServer (Kaas et al., 2012) , and their classification schemes and pharmacological activities have been extensively reviewed ).
Species differences in target receptors have played a critical role in the development of conotoxins as potential therapeutic agents.
One venom component, u-conotoxin MVIIA, paralyzes fish by targeting calcium channels at the neuromuscular junction. Although calcium channels at the human neuromuscular junction are resistant to u-conotoxin MVIIA, N-type calcium channels in the dorsal horn of the human spinal cord are highly sensitive to the same toxin. This discovery ultimately led to FDA approval of a chemically synthesized form of u-conotoxin MVIIA (ziconotide) for use in intractable pain. Another conotoxin, Vc1.1, a potent antagonist of rat a9a10 (ra9a10) nicotinic acetylcholine receptors (nAChRs) and an analgesic in rat models of neuropathic pain (Satkunanathan et al., 2005; Vincler et al., 2006) reached phase 2 human clinical trials.
However, the discovery that its potency at human a9a10 nAChRs in vitro was significantly less than in rat, prompted discontinuation of its clinical development.
A structurally novel 28-amino acid peptide, aO-conotoxin (aOCTx) GeXIVA, which potently blocks nAChRs, was recently discovered in the transcriptome of Conus generalis (Luo et al., 2015) . nAChRs are ligand-gated ion channels composed of five subunits, which are either all a subunits or a combination of a and non-a subunits. In mammals, there are nine different a subunits: a1ea7, a9, a10, four b subunits and g, d and ε subunits. GeXIVA displays high potency for a9a10 nAChRs. GeXIVA has four cysteine (Cys) residues in its primary sequence, which can be oxidized to form three possible disulfide isomers, referred to as the globular, ribbon and bead isomers. For convenience we hereafter denote them as GeXIVA [1, 3] , GeXIVA [1, 4] , and GeXIVA [1, 2] , respectively, with the numerals in square brackets referring to the first disulfide connectively in each of the isomers (with the 2nd disulfide connectivity following by default). Remarkably, each of these isomers shows antagonist activity at rat a9a10 nAChRs (Luo et al., 2015) .
Here we investigate the subtype-selectivity of each of the isomers on a range of rat nAChRs and at some human nAChR subtypes. We also probe the potential binding site of the peptide using 10 rat a9a10 receptor mutants.
Materials and methods

Peptide synthesis
The three isomers of aO-CTx GeXIVA were synthesized as previously described, whereby we used directed synthesis in a twostep oxidation procedure to enforce the disulfide arrangement (Luo et al., 2015) . Briefly, the linear peptide was assembled using solid-phase methodology on an ABI 433A peptide synthesizer using FastMoc (N-(9-fluorenyl) methoxycarbonyl) chemistry and standard side-chain protection, except for Cys residues. The Cys residues of the three isomers were protected in pairs with either Strityl on Cys20 and Cys27 (designated GeXIVA[1,2]), Cys9 and Cys27 (designated GeXIVA[1, 3] ), Cys9 and Cys20 (designated GeXIVA [1, 4] ), or S-acetamidomethyl on Cys2 and Cys9, Cys2 and Cys20, Cys2 and Cys27. The peptides were released from the solid support by treatment with reagent K (trifluoroacetic acid/water/ethanedithiol/phenol/thioanisole; 90:5:2.5:7.5:5, v/v/v/v/v). The released peptides were precipitated, washed three times with cold ether, and subjected to a two-step oxidation protocol to fold them selectively (Dowell et al., 2003; Walker et al., 1999) . The oxidized peptides were purified using high-performance liquid chromatography on a reversed-phase C18 Vydac column using a linear gradient of 10e50% B60 in 40 min. Solvent B (60% ACN, 40% H 2 0, 0.092% TFA); Solvent A (0.1% trifluoroacetic acid in H 2 O). Peptide concentration was measured using a spectrophotometer at a wavelength of 280 nm, and calculated using the Beer-Lambert equation. Matrix-assisted laser desorption ionization (MALDI) time-of-flight mass spectrometry and NMR spectroscopy were used to confirm the identity of the three disulfide isomers, as described in our earlier study (Luo et al., 2015) .
nAChR clones and cRNA preparation
Clones of rat a2ea7 and b2eb4, as well as mouse muscle a1b1dε cDNAs, were kindly provided by S. Heinemann (Salk Institute, San Diego, CA). Clones for rat a9 and a10 were kindly provided by A. B. Elgoyhen (INGEBI, Buenos Aires, Argentina). Clones of b2 and b3 subunits in the high-expressing pGEMHE vector were kindly provided by C.W. Luetje (University of Miami, Miami, FL). Clones of human a1b1dε were from Steven Sine (Mayo Clinic, Rochester, Minn). The human a6 clone was from Jon Lindstrom (Perelman School of Medicine, Philadelphia, PA). The other human subunits were from James Garrett (Formerly of Cognetix Inc., Salt Lake City, Utah). Clones for the human a9 and a10 subunits were kindly provided by Lawrence Lustig (Johns Hopkins University, Baltimore, MD). The human subunits were subcloned into the pSGEM vector for Xenopus oocyte expression. Capped cRNA for the various subunits were made using the mMessage mMachine in vitro transcription kit following linearization of the plasmid. The cRNA was purified using the Qiagen RNeasy kit. The concentration of cRNA was determined by absorbance at 260 nm.
Construction of rat a9a10 nAChR mutants
Rat a9 or a10 nAChR subunit clones were mutated using the QuikChange system (Stratagene) according to amino acid sequence alignment of N-terminal-binding regions of rat and human a9 and a10 nAChR subunits. In mutated ra9A24Ka10 nAChRs, the codon for Ala24 of the rat a9 subunit was replaced by a codon for Lys, and in ra9a10E61S nAChRs, the codon for Glu of the rat a10 subunit was replaced by a codon for Ser, and so on, as described previously (Azam and McIntosh, 2012) . Briefly, primers containing the desired point mutation flanked by at least 15 bases on either side were synthesized. Using the non-strand displacing action of Pfu Turbo DNA polymerase, the mutagenic primers were extended and incorporated by PCR. The methylated, non-mutated parental cDNA was digested with DpnI. The mutated DNA was transformed into DH10B or DH5a competent cells, isolated using the Qiaprep mini prep kit (Qiagen, Valencia, CA, USA), and sequenced to ascertain the incorporation of the desired mutation.
cRNA injection and expression
Xenopus oocytes were used to heterologously express cloned nAChR subtypes. Oocyte preparation, and expression of nAChR subunits in Xenopus oocytes were performed as described previously (McIntosh et al., 2005) . For rat a9 subunit mutants, cRNA of mutant a9 subunit were mixed at a 1:1 ratio with wild-type a10 for a final concentration of at least 500 ng/mL for each subunit cRNA.
For rat a10 subunit mutants, cRNA of mutant a10 subunit were mixed at a 1:1 ratio with wild-type a9. Fifty to 150 nL of this mixture was injected into each Xenopus oocyte using a Drummond microdispenser (Drummond Scientific, Broomall, PA), as described previously (Cartier et al., 1996) , which were incubated at 17 C. Oocytes were injected within a day of harvesting and recordings were made 2e5 days post-injection.
Electrophysiology
Oocytes were voltage-clamped and exposed to acetylcholine (ACh) and peptide, as described previously (Cartier et al., 1996) . The oocyte recording chamber was fabricated from Sylgard and was 30 mL in volume. All recordings were done at room temperature (~22 C). Briefly, oocytes were gravity-perfused with ND-96 buffer containing 1 mM atropine and 0.1 mg/ml BSA at a rate of~2 mL/min.
The ND-96 buffer, with a pH of 7.1e7.5, consisted of 96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl 2 , 1.0 mM MgCl 2 and 5 mM HEPES. In the case of rat and human a9a10, a7, and mouse muscle a1b1dε subtypes, to avoid antagonism of a7-like receptors atropine was omitted from the buffer (Cartier et al., 1996) . ACh-gated currents were obtained using a two-electrode voltage-clamp amplifier (model OC-725B, Warner Instruments, Hamden, CT). The membrane potential was clamped at À70 mV for all nAChR subtypes and mutants. The perfused oocyte was then subjected to a 1-sec pulse of 100 mM ACh once a minute repeatedly. In the case of rat and human a9a10 and mouse/human muscle a1b1dε subtypes a 1-sec pulse of 10 mM ACh was used, and for the rat and human a7 subtype a 1-sec pulse of 200 mM ACh was used. To measure conotoxin antagonism, peptide was bath-applied for 5 min before exposure to ACh. All ACh pulses contained no toxin.
Statistical analysis
The IC 50 values for the oocyte-expressing receptors are reported with 95% confidence intervals. The average of five control responses just preceding a test response was used to normalize the test response to obtain "percent response." IC 50 values were determined by nonlinear regression analysis using Prism (GraphPad Software, Inc., San Diego, CA, USA). All statistical analyses were performed with Prism. Each data point of a concentration-response curve represents the average ± S.E.M. of at least three oocytes.
Molecular modelling
The molecular models of the two binding modes of ribbon GeXIVA on the a9a10 nAChR that we proposed previously (Luo et al., 2015) were mutated using Modeller9v13 (Sali and Blundell, 1993) for use in the current study. The mutated models were minimised and submitted to 5 ns molecular dynamics simulations using Gromacs 2016 (Abraham et al., 2015) and the Amber99sb-ILDN force field (Lindorff-Larsen et al., 2010). Buried surface areas were computed using the Gromacs package.
Results
GeXIVA isomers are selective for ra9a10 nAChRs
The three disulfide isomers of GeXIVA were tested for their potency against the rat a9a10 (ra9a10) nAChR, as described previously (Luo et al., 2015) . We further investigated the effect of the three isomers on other subunit combinations of neuronal and muscle nAChRs heterologously expressed in Xenopus oocytes (Table 1 , Fig. 1 ). Concentration-response analysis indicated that, unlike most a-conotoxins, all three isomers displayed potency against a broad spectrum of rat nAChR subtypes. The three isomers most potently blocked the ra9a10 nAChRs. Generally, the three isomers displayed the lowest potency for subtypes containing the b4 nAChR subunit, and had little effect on ra2b4, ra3b4 and ra4b4 nAChRs, with IC 50 s > 869 nM.
Despite their potency, the three isomers exhibited differential sensitivity to rat nAChR subtypes. All three isomers were highly selective for ra9a10 nAChR, with IC 50 s ranging from 4.6 to 22.7 nM.
All three isomers were less potent on the rat a7 nAChR subtype. Of the isomers, GeXIVA [1, 2] was most potent at the ra7 nAChR subtype, with an IC 50 of 432 nM, which is 10-fold more potent than GeXIVA[1,3] (IC 50 : 4990 nM), and 4.1-fold more than GeXIVA[1,4] (IC 50 : 1768 nM). Unlike the ra9a10 and ra7 subtypes, the three isomers blocked the mouse muscle nAChR subtype (ma1b1dε) and the ra6/a3b2b3 subtype with similar potency: IC 50 s at these subtypes ranged from 394 to 683 nM and 369e555 nM, respectively ( Fig. 1 ). From these findings, we conclude that there are no differences between the three isomers in terms of potency and selectivity for the ma1b1dε, ra6/a3b2b3, and ra3b2 subtypes, but overall, their potency is far less at these receptors than at the rat and human a9a10 nAChRs. Thus, GeXIVA [1, 3] and GeXIVA [1, 4] are slightly less selective for ra9a10 nAChR than GeXIVA[1,2], but are 15-fold more selective for ra9a10 nAChR than the other aforementioned subtypes.
The order of potency of the isomers at the rat a9a10 subtype differed to that observed at the ra2b2, ra4b2, ra2b4, ra4b4, ra6/ a3b4 and ra3b4 subtypes (Table 3, Fig. 3 ). GeXIVA[1,4] displayed the greatest potency at ra2b2 and ra4b2, with IC 50 s of 122 nM at ra2b2, and an IC 50 of 215 nM at ra4b2. The IC 50 s of GeXIVA [1, 2] and GeXIVA [1, 3] at ra2b2 were 499 nM and 348 nM, respectively, and 1350 nM and 1261 nM, respectively, at ra4b2. GeXIVA [1, 4] and GeXIVA [1, 3] showed similar activities at ra2b4, ra4b4 and ra6/ a3b4. For these six subtypes, GeXIVA [1, 2] was the least active of the three isomers, which is interesting given that it had the highest selectivity and was at least 85-fold more potent at ra9a10 than the other subtypes.
GeXIVA isomers retain potency for ha9a10 nAChRs
The three GeXIVA isomers were tested for their ability to antagonize the response elicited by ACh on the human a9a10 (ha9a10) nAChR, and four closely related human subtypes ( Table 2 ).
The three isomers of GeXIVA block human a9a10 nAChRs differently. Fig. 2 shows representative responses of ha9a10 nAChRs to ACh in the presence and absence of the three GeXIVA isomers. The block of ha9a10 nAChR induced by both GeXIVA[1,2] and GeXIVA Luo et al. (2015) .
[1,3] was rapidly reversible ( Fig. 2A and B) , whereas that induced by GeXIVA[1,4] was slower to reverse (Fig. 2C) . The most potent isomer was found to be GeXIVA[1,2], which blocked ha9a10 nAChRs almost completely at 100 nM ( Fig. 2A) . GeXIVA [1, 3] was the least potent with a 57% response at 100 nM (Fig. 2B) . GeXIVA [1, 4] fell in the middle, with a 33% response at 100 nM (Fig. 2C) . Concentrationeresponse experiments were conducted ( 
GeXIVA isomers are selective for ha9a10 nAChR
The concentrationeresponse for the three isomers was assessed against each of the other closely related human nAChR subtypes (see Table 2 , Fig. 3 ). The most potent isomer at ha7 nAChR was GeXIVA 4] ), <1.4-fold different. GeXIVA [1, 3] and GeXIVA [1, 4] showed equal potency for ha6/a3b2b3, with IC 50 s of 149 nM and 199 nM, respectively. GeXIVA[1,2] was 2.6-fold less potent than GeXIVA [1, 4] , with an IC 50 of 508 nM. On the other hand, GeXIVA[1,2] was 25-fold more potent at the ha9a10 nAChR than at ha7, ha1b1dε and ha6/a3b2b3. GeXIVA [1, 3] showed similar activities on ha9a10 and ha6/a3b2b3, with closeIC 50 s; however, it was only weakly potent on ha7 e 31-fold less potent than ha9a10. GeXIVA [1, 4] was around 4e19-fold more potent at the ha9a10 nAChR than ha7, ha1b1dε and ha6/a3b2b3. All three isomers of GeXIVA retained selectivity for ha9a10 but not the other nAChR subtypes.
Effect of the isomers of GeXIVA on ra9a10 nAChR mutants
Mutations within the N-terminal ligand-binding domain of the a9 and a10 subunits of the rat nAChR were used to probe the binding site of GeXIVA. The activity of 10 nAChR a9 and a10 mutants (ra9T56Ia10, ra9S6Na10, ra9a10E61S, ra9a10D121L, ra9S117Aa10, ra9S14Na10, ra9S136Na10, ra9A24Ka10, ra9R71Ga10 and ra9E192Qa10) were measured for various concentrations of the three isomers (Table 3 , Fig. 4 ). All three isomers potently blocked the 10 ra9a10 nAChR mutants, and only small differences in affinity were observed; IC 50 s were similar to those seen for ha9a10 and although the isomers were less potent than at wild-type ra9a10 nAChRs, they were still within a 10-fold difference. The most potent isomer, GeXIVA[1,2], blocked the 10 ra9a10 mutants with IC 50 values ranging from 19.5 to 59.3 nM IC 50 s for GeXIVA [1, 4] ranged from 24 to 96 nM, and from 68 to 232 nM for GeXIVA [1, 3] . The order of potency of the isomers, in terms of the ra9a10 mutants was [1,2] ! [1,4] > [1,3], identical to the trend for inhibition of the rat and human wild-type receptors. . Oocytes expressing human a9a10 nAChR were voltage clamped at e 70 mV and subjected to a 1 s pulse of 10 mM ACh every minute as described in the Materials and Methods.
In panel A, B and C, the initial peaks are control responses, following which the oocyte was exposed to the peptide for 5 min. ND96 perfusion and ACh pulses were then resumed to monitor recovery from toxin block. The arrow denotes the current response trace on a9a10 nAChRs in the presence of 100 nM peptide. The bead isomer aO-GeXIVA[1,2] was most potent as it nearly completely blocked human a9a10 nAChR at 100 nM, whereas the globular aO-GeXIVA[1,3] was the least potent with only 43% block; the ribbon aO-GeXIVA [1, 4] had an intermediate activity with 67% block at 100 nM and its recovery was slower than the other two isomers.
Most of the mutations involved residues of the rat receptor being substituted by those of the human receptor, and the absence of measurable effects of these mutations is consistent with the very similar activity of the peptides whatever the origin of the receptor. Fig. 5 shows the location of the mutated positions on the ligandbinding domain of a9a10 nAChR, highlighting that the selected positions cover a large area of the receptor. Because these positions are widespread and because the mutations caused similar changes of activity, the impacts of the mutations on activity are not highly definitive. The positions that were mutated might therefore either not be part of the interface with the peptide ligands, or might be at the peptide binding interface but with the particular amino acids chosen for mutation not measurably impacting the binding affinity. Fig. 5 also displays the location of the two potential binding modes that were proposed previously for GeXIVA [1, 4] (Luo et al., 2015) . Only the two mutations ra9S6N and ra10D121L interrogate the proposed models, but mutations of these residues in the models lead to no change of hydrogen bonding and to a smaller than 4 Å 2 difference in contact surface area. The buried surface areas were 2720 Å 2 and 1700 Å 2 for the binding mode in the agonist binding site and the site at the outskirts of the pore, respectively. The mutations therefore cannot help prove or disprove the previously proposed models. Mutated positions ra9T56 and ra9S117 are located in the orthosteric binding site a10(þ)a9(À), which is distinct from the previously proposed binding mode of GeXIVA [1, 4] in the a9(þ)a10(À) orthosteric site or in the pore. It was previously suggested that GeXIVA [1,2] did not compete for binding with conotoxin RgIA (Luo et al., 2015) , which binds to the a10(þ)a9(À) binding site (Azam et al., 2015) . The mutation ra9T56I was shown to impact the activity of RgIA (Azam et al., 2015) , but the same mutation here had no measurable effect, further supporting the idea that the GeXIVA isomers do not bind to the a10(þ)a9(À) binding site.
Discussion
Both the bead and ribbon isomers of aO-CTx GeXIVA have previously been shown to significantly reduce mechanical hyperalgesia in the rat chronic constriction injury model of neuropathic pain without affecting motor performance (Li et al., 2016; Luo et al., 2015) . In those studies, the analgesic effects of GeXIVA [1, 2] and GeXIVA [1, 4] occurred at low doses ( 2 nmol) without tolerance issues. Although, in both cases, a 2 nmol intramuscular dose produced effects greater than or equal to that observed with 500 nmol of the opioid analgesic morphine (Li et al., 2016; Luo et al., 2015) , Li and colleagues observed the analgesic effects of GeXIVA[1,2] to be slightly better than GeXIVA[1,4] (Li et al., 2016) . Furthermore, they reported that the pain relieving effect of GeXIVA[1,2] remained for up to 2 weeks after cessation of drug administration. Like GeXIVA, the a-CTxs RgIA and Vc1.1 are known to be potent antagonists of ra9a10 nAChRs, and their potential as human therapeutics is being investigated (Lewis et al., 2012; Livett et al., 2006; McIntosh et al., 2009; Vincler et al., 2006) . When tested in rat models of neuropathic pain, both Vc1.1 and RgIA induced analgesia (Azam and McIntosh, 2012) . However, when human and rat nAChRs were compared, RgIA was found to be over 300-fold less potent at the ha9a10 nAChR (Table 4) (Azam and McIntosh, 2012) whereas Vc1.1 was found to be around 400-fold less potent at the ha9a10 nAChR compared to the rat receptor (Table 4) (Luo et al., 2015) . A molecular basis for the differential sensitivity of rat and human a9a10 nAChRs to RgIA was investigated (Azam and McIntosh, 2012) , and it was found that the primary determinant of this disparity is a single amino acid e a Thr56 (rat) to Ile56 (human). The current study aimed to further explore differences between rat and human receptors.
Vc1.1 reached phase 2A human clinical trials but trials were halted with the discovery that Vc1.1 had lower affinity for the ha9a10 nAChR compared to the ra9a10 nAChR (http://www. evaluategroup.com/Universal/View.aspx?type%3dStory%26id% 3d135083, Lewis et al., 2012) and in the absence of a clear efficacy signal. Subsequent reports indicated that Vc1.1 has potent GABA B agonist activity (Berecki et al., 2014; Callaghan and Adams, 2010; Callaghan et al., 2008; Craik et al., 2016; Cuny et al., 2012; c Data from Vincler et al., 2006 (Vincler et al., 2006 . Grishin et al., 2010) # ¼ C-terminus amidation.
Abbreviations: ra9a10 and ra3b4 means rat a9a10 and a3b4; ha9a10 means human a9a10; n.d. is "not determined"; and NA is "not active".
a B [1, 2] or [1, 2] is the "bead" isomer with a disulfide connectivity Cys1eCys2, Cys3eCys4 (C 1-2 , C 3-4 ). b G [1, 3] or [1, 3] is the "globular" isomer with a disulfide connectivity Cys1eCys3, Cys2eCys4 (C 1-3 , C 2-4 ). c R [1, 4] or [1, 4] is the "ribbon" isomer with a disulfide connectivity Cys1eCys4, Cys2eCys3 (C 1-4 , C 2-3 ). d Data from Luo et al., 2015 (Luo et al., 2015 .
e Ratio of quantity of a3 and b4 mRNA injected in oocytes.
et al., 2013). These findings have prompted an ongoing debate as to whether the analgesic mechanism of action of the a-conotoxins is via a9a10 nAChRs and/or GABA B receptors (Adams and Berecki, 2013; Christie, 2014, 2015; Wright et al., 2015; Romero et al., 2017) . The pharmacological profile of GeXIVA coupled with its demonstrated analgesia in rat models of neuropathic pain has prompted further interest in a9a10 nAChRs and
GeXIVA as a potential therapeutic agent (Luo et al., 2015; Li et al., 2016) . The present study supports a potential application of GeXIVA isomers in the treatment of neuropathic pain. All three isomers of GeXIVA have similar activities at the human and rat a9a10 nAChRs, with smaller than 5-fold differences (Table 4) . They have mid-to low-nanomolar IC 50 values (19.6e80.6 nM) for the rat a9a10 mutant ra9T56Ia10, which are similar to the values for the wildtype rat and human a9a10 receptors. In contrast, the IC 50 of aRgIA for ra9T56Ia10 is 2560 nMe1700-fold less than for ra9a10.
The potency of aD-CTx GeXXA (Xu et al., 2015) is 23.3-fold less for the human a9a10 receptor compared to the rat a9a10 receptor (Table 4) . Thus, among all of the aforementioned peptides, GeXIVA [1, 2] has the greatest affinity for ha9a10 nAChRs (IC 50 : 20 nM). This finding is consistent with the binding site of GeXIVA on rat and human a9a10 receptors being novel and distinct from that of aRgIA, a-Vc1.1 and aD-GeXXA.
a-Conotoxins are competitive blockers of nAChRs, with the blocking site of a9a10 nAChRs located at the a10/a9 subunit interface. A species difference renders these conotoxins orders of magnitude less potent on the human vs. rat nAChR (Azam and McIntosh, 2012; Azam et al., 2015; Yu et al., 2013) . In the present study, rat a9a10 nAChR mutants were used to compare the binding properties of the three isomers of GeXIVA (Fig. 4, Table 3 ) to those established for other conotoxins. All of the mutated ra9a10 receptors were found to have a similar affinity for the GeXIVA isomers as the wild-type rat and human a9a10 nAChRs, with a difference of <14-fold for rat and <3-fold for human. This finding confirms that GeXIVA binds different regions of a9a10 than those identified in aCTx RgIA and Vc1.1 and aD-CTx ligand-binding studies. Consistent with this, a previous study indicated that block by GeXVIA[1,2] was strongly voltage-dependent, suggesting that the toxin binding site might be allosterically coupled to a voltage-sensitive domain of the nAChR (Luo et al., 2015) .
a-Conotoxins with a CC-C-C cysteine framework typically comprise 12e20-amino acids and display a globular disulfide connectivity linking Cys 1 to 3, and 2 to 4. The alternative connectivities e ribbon (Cys1e4, 2e3) and bead (Cys1e2, 3e4) e are generally associated with lower potency. As an example, the native globular isomer of a-conotoxin GI is active at mammalian muscle nAChRs with full biological activity; however, the bead isomer is 10-fold less potent and the ribbon isomer has little or no biological activity (Gehrmann et al., 1998) . The ribbon a-GI isomer more readily rearranges to the native globular isomer than the bead isomer, according to stability studies in various assay buffers (Armishaw et al., 2010) . In one case, conotoxin a-AuIB, an alternative isomer was shown to be more active at the a3b4 receptor if the receptor contains three a3 and two b4 subunits, but not if the pentamer is formed by assembly of two a3 and three b4 subunits (Grishin et al., 2010) . The ribbon disulfide isomer a-AuIB has a less well-defined structure than the globular form (Dutton et al., 2002) , and the unexpected activity of the ribbon isomer a-AuIB may be ascribed to the structural flexibility of the molecule, which may allow for a more complementary fit in the binding site.
A disulfide bond between adjacent cysteines is energetically unfavorable, as is the case for the aB-CTx VxXXIVA which has a C-CC-C framework. In the case of GeXIVA, the bead isomer with the 1e2, 3e4 connectivity (GeXIVA[1,2]) blocks rat a9a10 nAChRs, and is 5e6 fold more active than the 1e3, 2e4 (GeXIVA [1, 3] ) form. VxXXIVA is atypical among disulfide-bridged conotoxins because it has disordered structures in aqueous solution over a range of temperatures and pHs (Luo et al., 2013 ). In the current study, all three isomers of the GeXIVA (C-C-C-C framework), blocked rat and human a9a10 nAChRs, with the order of potency being bead GeXIVA has a 'four separate' Cys pattern (C-C-C-C), whereas aconotoxins and aB-VxXXIVA have a 'two adjacent and two separate' Cys pattern (CC-C-C: a-CTx; C-CC-C: aB-CTx) ( Table 5 ). The difference in the functions of the disulfide bond isomers is reflected in the differences between their sequences, Cys arrangements, and three-dimensional structures.
The a9a10 nAChR is an important target for the development of analgesics and cancer chemotherapeutics (Chen et al., 2011; Chikova et al., 2012; Klimis et al., 2011; Satkunanathan et al., 2005; Wu et al., 2011) . The design and development of a*-conotoxin analogs with improved potency at human a9a10 nAChRs and that maintain selectivity over other nAChR subtypes, may especially assist in the treatment of neuropathic pain . The three isomers of GeXIVA have a unique selectivity among conotoxins as they potently inhibit both rat and human a9a10 nAChRs, potentially allowing a better translation of effects from animal models to the clinic.
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